Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population.

Piekarska A, Koślińska-Berkan E, Wójcik K, Skubała A, Jabłkowski M, Deroń Z, Berkan-Kawińska A.

Clin Exp Hepatol. 2016 Dec;2(4):133-137. doi: 10.5114/ceh.2016.63869. Epub 2016 Nov 28.

2.

Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice.

Papatheodoridi Μ, Dalekos GN, Goulis J, Manolakopoulos S, Triantos C, Zachou K, Koukoufiki A, Κourikou Α, Ζisimopoulos Κ, Τsoulas C, Papatheodoridis GV.

Ann Gastroenterol. 2017;30(5):542-549. doi: 10.20524/aog.2017.0170. Epub 2017 Jun 26.

3.

High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal.

Kjærgaard M, Thiele M, Jansen C, Stæhr Madsen B, Görtzen J, Strassburg C, Trebicka J, Krag A.

PLoS One. 2017 Apr 4;12(4):e0173992. doi: 10.1371/journal.pone.0173992. eCollection 2017.

4.

Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.

Degré D, Sersté T, Lasser L, Delwaide J, Starkel P, Laleman W, Langlet P, Reynaert H, Bourgeois S, Vanwolleghem T, Negrin Dastis S, Gustot T, Geerts A, Van Steenkiste C, de Galocsy C, Lepida A, Orlent H, Moreno C.

PLoS One. 2017 Jan 26;12(1):e0170933. doi: 10.1371/journal.pone.0170933. eCollection 2017.

5.

Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy.

Rivero-Juarez A, Lopez-Cortes LF, Castaño M, Merino D, Marquez M, Mancebo M, Cuenca-Lopez F, Jimenez-Aguilar P, Lopez-Montesinos I, Lopez-Cardenas S, Collado A, Lopez-Ruz MA, Omar M, Tellez F, Perez-Stachowski X, Hernandez-Quero J, Girón-Gonzalez JA, Fernandez-Fuertes E, Rivero A; HERACLES cohort study team of the Grupo de Estudio de Hepatitis Virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):487-494. doi: 10.1007/s10096-016-2822-6. Epub 2016 Oct 27.

6.

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.

Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, Chung RT, Curry MP, Hanifi JM, Gabardi S, Chandraker A, Heher EC, Elias N, Riella LV.

PLoS One. 2016 Jul 14;11(7):e0158431. doi: 10.1371/journal.pone.0158431. eCollection 2016.

7.

Management of HCV-Associated Liver Cirrhosis.

Schneider MD, Sarrazin C.

Visc Med. 2016 Apr;32(2):96-104. doi: 10.1159/000445330. Epub 2016 Apr 8. Review.

8.

Systemic manifestations of hepatitis C infection.

Tang L, Marcell L, Kottilil S.

Infect Agent Cancer. 2016 May 23;11:29. doi: 10.1186/s13027-016-0076-7. eCollection 2016. Review.

9.

Thrombin activation and liver inflammation in advanced hepatitis C virus infection.

González-Reimers E, Quintero-Platt G, Martín-González C, Pérez-Hernández O, Romero-Acevedo L, Santolaria-Fernández F.

World J Gastroenterol. 2016 May 14;22(18):4427-37. doi: 10.3748/wjg.v22.i18.4427. Review.

10.

Recent Advances in Antiviral Therapy for Chronic Hepatitis C.

Tamori A, Enomoto M, Kawada N.

Mediators Inflamm. 2016;2016:6841628. doi: 10.1155/2016/6841628. Epub 2016 Jan 31. Review.

11.

Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C Virus.

Voulgaris T, Sevastianos VA.

Hepat Res Treat. 2016;2016:7629318. doi: 10.1155/2016/7629318. Epub 2016 Jan 13. Review.

12.

Entry inhibitors: New advances in HCV treatment.

Qian XJ, Zhu YZ, Zhao P, Qi ZT.

Emerg Microbes Infect. 2016 Jan 6;5:e3. doi: 10.1038/emi.2016.3. Review.

13.

Evaluation of Percutaneous Liver Biopsy Complications in Patients with Chronic Viral Hepatitis.

Kose S, Ersan G, Tatar B, Adar P, Sengel BE.

Eurasian J Med. 2015 Oct;47(3):161-4. doi: 10.5152/eurasianjmed.2015.107.

14.

The New Era of Interferon-Free Treatment of Chronic Hepatitis C.

Solbach P, Wedemeyer H.

Viszeralmedizin. 2015 Aug;31(4):290-6. doi: 10.1159/000433594. Epub 2015 Aug 6. Review.

15.

Microfibrillar-Associated Protein 4: A Potential Biomarker for Screening for Liver Fibrosis in a Mixed Patient Cohort.

Sækmose SG, Mössner B, Christensen PB, Lindvig K, Schlosser A, Holst R, Barington T, Holmskov U, Sorensen GL.

PLoS One. 2015 Oct 13;10(10):e0140418. doi: 10.1371/journal.pone.0140418. eCollection 2015.

16.

Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.

Sukeepaisarnjaroen W, Pham T, Tanwandee T, Nazareth S, Galhenage S, Mollison L, Totten L, Wigg A, Altus R, Colman A, Morales B, Mason S, Jones T, Leembruggen N, Fragomelli V, Sendall C, Guan R, Sutedja D, Tan SS, Dan YY, Lee YM, Luman W, Teo EK, Than YM, Piratvisuth T, Lim SG.

World J Gastroenterol. 2015 Jul 28;21(28):8660-9. doi: 10.3748/wjg.v21.i28.8660.

17.

A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.

Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Müllhaupt B, Metzner KJ, Decosterd L, Böni J, Weber R, Fehr J; Swiss HIV Cohort Study.

PLoS One. 2015 Jul 15;10(7):e0133028. doi: 10.1371/journal.pone.0133028. eCollection 2015. Erratum in: PLoS One. 2015;10(8):e0135547.

18.

Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.

Hu CC, Lin CL, Chang LC, Chien CH, Chen LW, Liu CJ, Chien RN.

BMC Infect Dis. 2015 Mar 26;15:156. doi: 10.1186/s12879-015-0888-x.

19.

Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy.

Miyanishi K, Hoki T, Tanaka S, Kato J.

World J Hepatol. 2015 Mar 27;7(3):593-9. doi: 10.4254/wjh.v7.i3.593. Review.

20.

Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits.

Smith-Palmer J, Cerri K, Valentine W.

BMC Infect Dis. 2015 Jan 17;15:19. doi: 10.1186/s12879-015-0748-8. Review.

Supplemental Content

Loading ...
Support Center